145 related articles for article (PubMed ID: 16762624)
61. Dissection of DEN-induced platelet proteome changes reveals the progressively dys-regulated pathways indicative of hepatocarcinogenesis.
Leng T; Liu N; Dai Y; Yu Y; Zhang C; Du R; Chen X
J Proteome Res; 2010 Dec; 9(12):6207-19. PubMed ID: 20919743
[TBL] [Abstract][Full Text] [Related]
62. [Differential analysis of tyrosine-phosphorylated proteins in human hepatocellular carcinoma cell lines with different metastasis potentials].
Zhang LJ; Cui JF; Liu YK; Zhu YS; Song HY; Shen HL; Feng JT; Dai Z; Chen J; Sun RX
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):436-9. PubMed ID: 15975278
[TBL] [Abstract][Full Text] [Related]
63. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer.
Xia Q; Kong XT; Zhang GA; Hou XJ; Qiang H; Zhong RQ
Biochem Biophys Res Commun; 2005 May; 330(2):526-32. PubMed ID: 15796914
[TBL] [Abstract][Full Text] [Related]
64. [Protein profiles of multinodular hepatocellular carcinoma with multicentric occurrence or with intrahepatic metastasis].
LI M; GUO K; KANG XN; SUN L; SHU H; LI RL; XU MH; LIU YK; QIN X; LI S
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):354-8. PubMed ID: 19497201
[TBL] [Abstract][Full Text] [Related]
65. Aberration of genomic DNA in association with human hepatocellular carcinomas detected by 2-dimensional gel analysis.
Nagai H; Ponglikitmongkol M; Mita E; Ohmachi Y; Yoshikawa H; Saeki R; Yumoto Y; Nakanishi T; Matsubara K
Cancer Res; 1994 Mar; 54(6):1545-50. PubMed ID: 8137261
[TBL] [Abstract][Full Text] [Related]
66. Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery.
Lee YY; McKinney KQ; Ghosh S; Iannitti DA; Martinie JB; Caballes FR; Russo MW; Ahrens WA; Lundgren DH; Han DK; Bonkovsky HL; Hwang SI
J Proteome Res; 2011 Nov; 10(11):5070-83. PubMed ID: 21913717
[TBL] [Abstract][Full Text] [Related]
67. [Comparison of the Golgi proteome of hepatocellular carcinoma with that of the adjacent non-tumor tissues].
Xiao Z; Yi YF; He TT; Li YQ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):23-6. PubMed ID: 20128964
[TBL] [Abstract][Full Text] [Related]
68. Myofibroblasts are important contributors to human hepatocellular carcinoma: evidence for tumor promotion by proteome profiling.
Slany A; Haudek-Prinz V; Zwickl H; Stättner S; Grasl-Kraupp B; Gerner C
Electrophoresis; 2013 Dec; 34(24):3315-25. PubMed ID: 24115093
[TBL] [Abstract][Full Text] [Related]
69. Genomic analysis of human hepatocellular carcinomas using Restriction Landmark Genomic Scanning.
Nagai H; Hirotsune S; Komatsubara H; Hatada I; Mukai T; Hayashizaki Y; Matsubara K
Cancer Detect Prev; 1993; 17(3):399-404. PubMed ID: 8402726
[TBL] [Abstract][Full Text] [Related]
70. [Proteome analysis of autoantibodies in sera of patients with cancer].
Ueda K
Rinsho Byori; 2005 May; 53(5):437-45. PubMed ID: 15966408
[TBL] [Abstract][Full Text] [Related]
71. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas.
Zeindl-Eberhart E; Haraida S; Liebmann S; Jungblut PR; Lamer S; Mayer D; Jäger G; Chung S; Rabes HM
Hepatology; 2004 Feb; 39(2):540-9. PubMed ID: 14768008
[TBL] [Abstract][Full Text] [Related]
72. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C.
Blanc JF; Lalanne C; Plomion C; Schmitter JM; Bathany K; Gion JM; Bioulac-Sage P; Balabaud C; Bonneu M; Rosenbaum J
Proteomics; 2005 Sep; 5(14):3778-89. PubMed ID: 16097030
[TBL] [Abstract][Full Text] [Related]
73. [Development of the new tumor markers].
Terashima K
Rinsho Byori; 2005 Mar; 53(3):234-8. PubMed ID: 15839053
[TBL] [Abstract][Full Text] [Related]
74. [Two-dimensional gel electrophoresis of subcellular fractions of hepatoma cells].
Li X; Pan W; Qiu F; Tian KL; Qiu ZY
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):271-3. PubMed ID: 15850514
[TBL] [Abstract][Full Text] [Related]
75. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.
Looi KS; Nakayasu ES; Diaz RA; Tan EM; Almeida IC; Zhang JY
J Proteome Res; 2008 Sep; 7(9):4004-12. PubMed ID: 18672925
[TBL] [Abstract][Full Text] [Related]
76. Nuclear matrix of calreticulin in hepatocellular carcinoma.
Yoon GS; Lee H; Jung Y; Yu E; Moon HB; Song K; Lee I
Cancer Res; 2000 Feb; 60(4):1117-20. PubMed ID: 10706133
[TBL] [Abstract][Full Text] [Related]
77. Identification of calreticulin as a nuclear matrix protein associated with human colon cancer.
Brünagel G; Shah U; Schoen RE; Getzenberg RH
J Cell Biochem; 2003 May; 89(2):238-43. PubMed ID: 12704787
[TBL] [Abstract][Full Text] [Related]
78. Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by iTRAQ-based quantitative proteomics.
Xing X; Huang Y; Wang S; Chi M; Zeng Y; Chen L; Li L; Zeng J; Lin M; Han X; Liu X; Liu J
J Proteomics; 2015 Oct; 128():262-71. PubMed ID: 26300425
[TBL] [Abstract][Full Text] [Related]
79. A protein-based set of reference markers for liver tissues and hepatocellular carcinoma.
Sun S; Yi X; Poon RT; Yeung C; Day PJ; Luk JM
BMC Cancer; 2009 Sep; 9():309. PubMed ID: 19725976
[TBL] [Abstract][Full Text] [Related]
80. Hepatocellular carcinoma: from bedside to proteomics.
Seow TK; Liang RC; Leow CK; Chung MC
Proteomics; 2001 Oct; 1(10):1249-63. PubMed ID: 11721636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
